United States: FDA's Fifth Draft Guidance On Biosimilars Sheds New Light On Approval Pathway

Last Updated: May 28 2014
Article by Colleen Heisey

On May 13, the U.S. Food & Drug Administration ("FDA") issued a draft guidance, Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. The draft guidance is intended to assist biological product sponsors with the design and use of clinical pharmacology studies to support a showing that a proposed therapeutic biological product is "biosimilar" to its reference product under the Biologics Price Competition and Innovation Act of 2009 ("BPCI Act"). The draft guidance specifically relates to products such as therapeutic biologics, for which pharmacokinetic ("PK") and pharmacodynamic ("PD") data are required as part of a "stepwise" approach to developing the data and information needed to demonstrate biosimilarity. As the most detailed guidance yet on evidence needed to establish biosimilarity, the draft guidance adds further clarity to the cost of bringing a biosimilar to market.

In granular detail, the draft guidance covers overarching concepts related to clinical pharmacology testing for biosimilars, approaches for developing the appropriate clinical pharmacology database, and the utility of modeling and simulation for designing clinical trials. Notably, the draft guidance introduces the Agency's expectations for bridging data from products marketed outside of the United States and lays out key topics about which sponsors should meet with FDA early on in the biosimilar development process. The encouragement of early meetings with FDA echoes the Agency's stepwise approach to biosimilar approval, suggested in earlier draft guidance, which allows a sponsor to undertake research, identify areas of uncertainty, and then tailor future research to address those areas of uncertainty. 

The draft guidance introduces four categories of similarity—not similar, similar, highly similar, and highly similar with fingerprint-like similarity—that will affect the extent to which further study is needed to establish biosimilarity. The category of "fingerprint-like similarity" may preview FDA's thought process on the concept of interchangeability, which is the level of biosimilarity necessary for possible substitution of a biosimilar for a reference product at the pharmacy level. 

Once finalized, the draft guidance will be part of a series of guidance documents intended to implement the BPCI Act. These guidances are meant to help sponsors design clinical pharmacology studies needed to support an application for licensure of a biosimilar biologic. In February 2012, FDA released the first three draft guidances on biosimilar product development, followed by a fourth guidance released in March 2013. Collectively, these previous draft guidance documents provided relatively general principles concerning the biosimilars application process, and this latest draft guidance adds a level of detail not previously provided. Additional guidance documents are expected on topics such as interchangeability, labeling, and exclusivity.

Biosimilarity and the Role of Clinical Pharmacology 

The BPCI Act was enacted as a provision of the Patient Protection and Affordable Care Act and establishes an abbreviated route to FDA licensure of biological products shown to be "biosimilar" to and, possibly in addition, "interchangeable" with, an FDA-licensed reference product (the innovator, or brand-name, biological product). A biological product is a therapy used to treat a disease or health condition, such as vaccines, blood and blood components, gene therapies, tissues, and proteins. Biological products differ from small-molecule drugs in that they are made by cellular processes or biotechnology. In addition, as compared to small-molecule drugs, biologics are large, complex molecules that are relatively difficult to characterize and complex to manufacture. Biologics provide treatment for very serious diseases, including cancer and diabetes, but they are extremely expensive to develop. The intended effect of the BPCI Act is to increase competition for biologics, thereby reducing prices and expanding access to these drugs. 

A biological product may be demonstrated to be "biosimilar" to a reference product if data shows that the product is "highly similar" to the reference product, notwithstanding minor differences in clinically inactive components, and that there are "no clinically meaningful differences" between the biological product and the reference product in terms of safety, purity, and potency. 

To apply for the abbreviated licensure, the applicant must demonstrate in its biosimilar application ("351(k) application") that the product:

  • Is a "biosimilar" to the reference product (as set forth above);
  • Utilizes the same mechanism(s) of action for the proposed condition(s) of use;
  • Has condition(s) of use proposed in labeling that have been previously approved for the reference product; and
  • Has the same route of administration, dosage form, and strength as the reference product.

The 351(k) application must be based on data derived from analytical studies, animal studies, and a clinical study or studies, including an assessment of immunogenicity, PK, and PD, unless FDA determines that such studies are unnecessary in the application. Clinical pharmacology studies—initial research done on small groups of human subjects—are of particular importance to support a showing of biosimilarity by demonstrating no clinically meaningful differences between the proposed biosimilar and the reference product. These studies are intended to act as a roadmap for the design of subsequent clinical testing needed to demonstrate no clinically meaningful differences between the biosimilar and the reference product. 

Key Concepts in the Use of Clinical Pharmacology Studies to Support Biosimilarity 

The draft guidance provides a detailed discussion of the concepts of exposure and response, assessment, evaluation of residual uncertainty, and assumptions about analytical quality and similarity, all of which are highly relevant to the development of proposed biosimilars. This section also examines bioanalytical methodology and the use of clinical pharmacology to acquire information on safety and immunogenicity.

Exposure and Response Assessment to Support a Demonstration of Biosimilarity. The draft guidance provides that a well-designed clinical PK and PD study evaluates the similarities and differences in the PK and PD profiles between the proposed biosimilar and the reference product. Exposure-response information can be used to determine safety, purity, and potency of any biologic, as well as to determine any potential clinically meaningful differences between the two products. However, determining the response to exposure to a biologic is challenging due to the complexity of these products that make up the active component. The draft guidance details the PD marker(s) and other biomarkers that should be used to provide maximum value to such studies. 

Evaluation of Residual Uncertainty. FDA considers the totality of data and information submitted in evaluating a sponsor's data to support a demonstration of biosimilarity, including data from the structural and functional characterization, nonclinical evaluations, human PK and PD studies, clinical immunogenicity testing, and investigation of clinical safety. The draft guidance advises sponsors to collect such information in a stepwise manner and notes that PK, PD, and safety data obtained in conjunction with the clinical pharmacology studies is particularly pertinent to FDA's clinical pharmacology evaluation. Whether additional studies at each step are needed will be determined by the degree of residual uncertainty remaining with respect to the similarity of the products. 

Assumptions About Analytical Quality and Similarity. Sponsors should perform extensive and robust comparative structural and functional studies, such as bioassays, binding assays, and studies of enzyme kinetics, to evaluate whether the proposed biosimilar and the reference product are highly similar. The draft guidance provides as an example that a meaningful assessment depends in part on the capabilities of analytical assays to assess the molecular weight of the protein, its higher order structure and post-translational modifications, heterogeneity, functional properties, impurity profiles, and degradation profiles denoting stability.

If the analytical characterization reveals differences between the proposed biosimilar and the reference product, the sponsor should clearly identify the type, nature, and extent of these differences and address their potential impact. The draft guidance suggests one of four results for a comparative analytical characterization, the outcome of which will inform the sponsor's next steps in the demonstration of biosimilarity: 

  • Not Similar. A proposed biosimilar that receives the characterization of "not similar" is not advised to undertake further steps in the 351(k) process, unless modifications can be made that are likely to lead to a highly similar biological product.
  • Similar. If a proposed biosimilar receives the characterization of "similar," the sponsor needs to present additional information to determine whether the product is "highly similar" to the reference product.
  • Highly Similar. Based on the results of the comparative analytical characterization, the proposed biosimilar meets the statutory standard for analytical similarity. A sponsor with this product characterization should next conduct targeted and selective animal and/or clinical studies to resolve residual uncertainty and support a demonstration of biosimilarity.
  • Highly Similar with Fingerprint-Like Similarity. The proposed biosimilar meets the statutory standard for analytical similarity "based on integrated, multi-parameter approaches that are extremely sensitive in identifying analytical differences." These results indicate "a very high level of confidence in the analytical similarity of the proposed biosimilar and the reference product," and sponsors should proceed with a more targeted and selective approach to conducting animal and/or clinical studies to resolve residual uncertainty and support a demonstration of biosimilarity.

Integrity of the Bioanalytical Methods Used in PK and PD studies. Sponsors should be sure to use the appropriate bioanalytical methods when evaluating the PK and PD properties of a proposed biosimilar and its reference product. The complex molecular structure of biologics may render conventional analytical methods for chemical drugs unsuitable. Thus, sponsors should ensure that the bioanalytical methods used for PK and PD evaluations are "accurate, precise, specific, sensitive, and reproducible." FDA further describes the requirements of bioanalytical methods in a separate guidance document, Bioanalytical Method Validation.

The draft guidance details three specific considerations for sponsors in designing bioanalytical methods for biosimilars:

General PK Assay Considerations. How sponsors should design or choose assays with regard to the mechanism of action and structural elements of the proposed biosimilar.

General PK and PD Assay Considerations. How sponsors should employ the most suitable assays and methodologies with the goal of obtaining data that reflects drug exposure, biological activity, and/or the PD effect of the proposed biosimilar and reference product. \

Specific Assays. Sponsors should keep in mind three types of assays of particular importance for biosimilar development:

  • Ligand Binding Assays. Ligand binding assays are currently used to measure the concentration of most biological products in circulation. These assays are analytical methods in which quantification is based on macromolecular interactions with assay reagents.
  • Concentration and Activity Assays. Bioanalytical methods that are not based on ligand binding can be used to quantify the concentrations of the proposed biosimilar and reference products. For some biologics, these measurements may rely on activity assays.
  • PD Assays. If PD markers are not available to support a proposed biosimilar's development through clinical pharmacology studies, but the PD assessment is a piece of the biosimilarity evaluation, sponsors are advised to provide FDA with a rationale for the selection of PD endpoints and/or markers, along with data to demonstrate the assay quality. 

Safety and Immunogenicity. The draft guidance defines "immunogenicity" in this context as "an immune response to the biological product that may result in immune-mediated toxicity and/or lack of effectiveness." Sponsors should collect and evaluate safety and immunogenicity data from the clinical pharmacology studies, although FDA does recognize that such studies may need to be supplemented by additional evaluations either pre- or post-approval. FDA nonetheless stresses that clinical pharmacology studies may suggest "clinically meaningful differences" between the two products, which may indicate the need for further investigation. 

Sponsors should also consider the reference product's publicly available safety and immunogenicity profile when designing clinical pharmacology studies for the proposed biosimilar. FDA provided recommendations for immunogenicity assay development in a previous draft guidance document, Assay Development for Immunogenicity Testing of Therapeutic Proteins

Developing Clinical Pharmacology Data for Supporting a Demonstration of Biosimilarity 

The draft guidance encourages sponsors to discuss "the crucial aspects of their clinical pharmacology development plan" with FDA early on. Specifically, sponsors should discuss the following design topics with FDA early in the development of the biosimilar program: 

Study Design. The draft guidance describes two study designs of particular importance for evaluating clinical PK and PD similarity for proposed biosimilars:

  • Crossover Design. Crossover designs are single-dose, randomized studies recommended for PK similarity assessments for a product with a short half-life (e.g., shorter than five days), a rapid PD exposure (e.g., onset, maximal effect, and disappearance in conjunction with drug exposure), and a low incidence of immunogenicity. The draft guidance recommends multiple doses for PD similarity assessments when the PD effect is delayed or otherwise not parallel to the single-dose drug PK profile.
  • Parallel Design. Parallel designs are appropriate for biologics with a long half-life that elicit immunogenetic responses that can affect PK and/or PD similarity assessments.

Reference Product. The BPCI Act defines a "reference product" for a proposed biosimilar as the single biological product licensed under section 351(a) of the Public Health Service Act against which a proposed biosimilar is evaluated in a 351(k) application. To support biosimilarity, a sponsor must include analytical studies and at least one clinical PK and, if appropriate, PD study to adequately compare the proposed biosimilar to the U.S.-licensed reference product. Additionally, the draft guidance indicates that for certain studies, a sponsor may use a non-U.S. licensed comparator product to support a demonstration of biosimilarity, noting that the sponsor must then provide sufficient data to scientifically justify use of the non-U.S. licensed product and "establish an acceptable bridge to the U.S.-licensed reference product." The draft guidance further explores the requirements for the bridging data. The FDA statements regarding foreign data usage represent welcome progress to many in the industry, although it is too soon to evaluate their practical significance in product development.

Study Population. The draft guidance describes two study populations of particular importance for evaluating clinical PK and PD similarity for proposed biosimilars:

  • Healthy Volunteer vs. Patient. The chosen study population should be that which best detects and evaluates differences in PK and PD profiles between the proposed biosimilar and the reference product. Human PK and PD studies should ideally be conducted in healthy volunteers, provided the sponsor can safely administer the product, because such studies are more sensitive in evaluating biosimilarity. If safety or efficacy concerns prevent the use of healthy volunteers, sponsors should conduct the clinical pharmacology studies in patients.
  • Demographic Group. Sponsors should conduct clinical pharmacology studies in the subject or patient demographic group most capable of providing a sensitive measure of the differences between the proposed biosimilar and the reference product. Sponsors must also provide justification for the chosen demographic.

Dose Selection. The selected dose should be the most sensitive to detecting and evaluating the differences in the PK and PD profiles between the proposed biosimilar and the reference product. For example, for studies conducted in patients, the most suitable choice may be the approved dose for the reference product, as it may best demonstrate the pharmacological effects in a clinical setting. The draft guidance provides variations to this general suggestion based on other circumstances, such as healthy subjects or measuring PD.

Route of Administration. Sponsors should conduct human PK and PD studies with the same route of administration as that used for the reference product. For a reference product with more than one approved route of administration, sponsors should select the route most sensitive for detecting clinically meaningful differences (typically the subcutaneous or other extravascular routes).

Pharmacokinetic Measures. Sponsors should obtain all PK measures for the proposed biosimilar and the reference product. Specifically, the draft guidance provides details as to how sponsors should obtain Cmax and total exposure.

Pharmacodynamic Measures. In some circumstances, human PK and PD data showing similar exposure and response between a proposed biosimilar and a reference product may be enough to assess clinically meaningful differences between the products. The draft guidance describes when such circumstances occur and notes that full safety and immunogenicity evaluations are nonetheless required either before or after approval. If human PK and PD data is insufficient to completely assess for clinically meaningful differences, a targeted approach to gather additional data may be needed. The draft guidance describes what criteria will determine such subsequent targeted steps. 

Defining the Appropriate Pharmacodynamic Time Profile. The best sampling strategy for determining PD measures may not be the same as that used for PK measures. PK sampling may require frequent sampling at early time points after administration, with decreased frequency later on. In contrast, PD sampling may differ, and sponsors should explain these differences. 

Statistical Comparison of PK and PD Results. FDA's recommended clinical pharmacology similarity assessments rely on: (i) a criterion to allow the comparison, (ii) a confidence interval for the criterion, and (iii) an acceptable limit. Sponsors should perform log-transformation of the exposure measures prior to statistical analysis. FDA's earlier guidance, Statistical Approaches to Establishing Bioequivalence, can provide sponsors with an average equivalence statistical approach to comparing PK and PD parameters for both replicate and nonreplicate design studies. This section provides the confidence interval for the ratios between the means of the parameters of the proposed biosimilar and the reference product. If results of the PK and/or PD study fall outside the predefined limits, and such results may indicate underlying differences between the two products, sponsors should explain such differences. Notably, however, the draft guidance states that "[i]f such differences do not translate into clinically meaningful differences and the safety, purity, and potency of the product are not affected, it may be possible to continue developing under the 351(k) pathway."

Utility of Simulation Tools in Study Design and Data Analysis

The draft guidance suggests the usefulness of modeling and simulation tools for designing PK and PD studies. Specifically, for biomarker-based comparisons, sponsors should select a dose on the steep portion of the dose-response curve of the reference product and provide data to support the claim that the selected dose falls on this steep curve. Sponsors may use publicly available data for the dose-response relationship of the reference product to analyze using simulations in order to justify the selected dose for the PK and/or PD study. If such data is not available for the reference product, the sponsor may generate this information using a small study.

Conclusion

The draft guidance concludes by reiterating the critical role of clinical pharmacology studies in the development of biosimilars. Specifically, these studies are "part of a stepwise process for demonstrating biosimilarity between a proposed biosimilar product and the reference product and add to the totality of the evidence to support an overall demonstration of biosimilarity...." 

Comments Should Be Submitted by August 12

To ensure that FDA considers comments before issuing the final version of the draft guidance, FDA encourages industry to submit comments on the draft guidance by August 12. Comments can be submitted electronically to http://www.regulations.gov [Docket No. FDA–2014–D–0234].

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Colleen Heisey
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.